1999.9－2004.7   河北医科大学                    临床医学专业    本科

2004.9－2007.6   河北医科大学                    病原生物学      硕士

2007.7－2009.11   河北医科大学病原生物学教研室    助教

2009.12－2014.11  河北医科大学病原生物学教研室    讲师

2013.9－2016.7   中国疾病预防控制中心病毒病所    病原生物学      博士

2014.12－2019.2   河北医科大学病原生物学教研室    副教授

2019.3－2023.6   中国科学院上海巴斯德研究所      副研究员

2023.7－2023.9   中国科学院上海免疫与感染研究所  副研究员

2023.10－至今   中国科学院上海免疫与感染研究所  研究员

1. Sun K^#, Ding Z^#, Jia X^#, Cheng H^#, Li Y, Wu Y, Li Z, Huang X, Pu F, Li E, Wang G, Wang W, Ding Y, Gary Wong, Chiu S*, Lan J*, Hu A*. Extracellular Disintegration of Viral Proteins as an Innovative Strategy for Developing Broad-Spectrum Antivirals Against Coronavirus. CCS Chemistry. 2024, 6, 487–496. (Co-Corresponding Author)
2. Lu M^#, Yao Y^{# *}, Liu H, Zhang X, Li X, Liu Y, Peng Y, Chen T, Sun Y, Gao G, Chen M, Zhao J, Zhang X, Yin C, Guo W, Yang P, Hu X, Rao J, Li E, Gary Wong, Yuan Z*, Chiu S*, Shan C* Lan J*. Vaccines based on the fusion protein consensus sequence protect Syrian hamsters from Nipah virus infection. Jci Insight. 2023，8(23): e175461. (Co-Corresponding Author)
3. Lu M^#, Yao Y^{#, *}, Zhang X, Liu H, Gao G, Peng Y, Chen M, Zhao J, Zhang X, Yin C, Guo W, Yang P, Hu X, Rao J, Li E, Chen T, Chiu S, Gary Wong, Yuan Z*, Lan J*, Shan C*. Both chimpanzee adenovirus-based and DNA vaccines induced long-term immunity and conferred complete protection against Nipah virus infection. npj Vaccines. 2023，8(1):170. (Co-Corresponding Author)
4. Lu M^#, Liu K^#, Peng Y^#, Ding Z^#, Li Y, Alexander T, Hu X, Gao G, Guo W, Liu H, Rao J, Zhao J, Chen M, Yuan Z, Wong G*, Shan C*, Yao Y*, Lan J*. Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virol Sin. 2022，37(4):581-590. (Co-Corresponding Author).
5. Shen L^#, Li S^#, Zhu Y^#, Zhao J^#, Tang X^#, Li H, Xing H, Lu M, Frederick C, Huang C, Wong G*, Wang C*, Lan J*. Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China. J Infect. 2020, pii: S0163-4453(20)30166-3.(Co-Corresponding Author).
6. Shen L^#, Wang C^#, Zhao J^#, Tang X^#, Shen Y^#, Lu M, Ding Z, Huang C, Zhang J, Li S, Lan J*, Wong G*, Zhu Y*. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect. 2020，9(1):1096-1101. (Co-Corresponding Author).
7. Yang R^#, Lan J^#, Huang B, A R, Lu M, Wang W, Wang W, Li W, Deng Y*, Wong G*, Tan W*. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine. 2020,58:102890. (Co-First Author;).
8. Lan J^#, Deng Y, Song J, Huang B, Wang W, Tan W*. Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin. 2018 ,33(5):453-455. (Co-First Author).
9. Deng Y^#, Lan J^#, Bao L^#, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W*. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect. 2018 ,7(1):60. (Co- First Author).
10. Lan J^#, Yao Y^#, Deng Y^#, Hu Y, Bao L, Huang B, Yan J, Gao GF, Qin C, Tan W*. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017 ,35(1):10-18. (Co-First Author).
11. Liu WJ^#, Lan J^#, Liu K^#, Deng Y^#, Yao Y^#, Wu S, Chen H, Bao L, Zhang H, Zhao M, Wang Q, Han L, Chai Y, Qi J, Zhao J, Meng S, Qin C, Gao GF*, Tan W*. Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8⁺ T Cell Epitopes and Host MHC. J Immuno.2 017 ,198(2):873-882. (Co-First Author).

作为课题负责人承担国家级、省部级和厅局级课题共11项，目前在研中科院先导B项目1项、国家自然科学基金面上项目1项、上海市科创行动计划项目1项。

研究主要围绕以下三个方向：

（1）埃博拉病毒为生物安全四级病毒，目前发现6种埃博拉病毒，分别为扎伊尔埃博拉病毒（ZEBOV)、苏丹埃博拉病毒（SUDV)、Taï森林埃博拉病毒（TAFV)、莱斯顿埃博拉病毒RESTV)、本迪布焦埃博拉病毒（BDBV）和邦巴利埃博拉病毒（BOMV)。已知ZEBOV、SUDV和BDBV可引起非常严重且通常致命的疾病，患者可表现为出血热、低血容量性休克和/或器官衰竭，病死率高达90%。埃博拉病毒现已在非洲以外的许多国家发生，对全球公共卫生和安全构成严重威胁，迫切需要针对这一致命病原体开发安全有效的疫苗并优化部署策略，防范未来埃博拉疫情暴发。

（2）蝙蝠传播的尼帕病毒为生物安全四级病毒，代表性毒株有马来西亚株和孟加拉株，两者在传播途径和致病性方面均存在较大差异，在探讨两者差异机制的同时，研发可同时保护该两株或更多尼帕毒株感染的疫苗、抗体和药物等抗病毒策略。

（3）人冠状病毒有9种，包括季节性冠状病毒和高致病性冠状病毒两大类，两类冠状病毒在多个蛋白中存在保守功能结构域，研究保守功能结构域，探讨季节性冠状病毒感染后对高致病性冠状病毒感染的影响，为高致病性冠状病毒的诊断和抗病毒策略研发提供理论和实验依据。

实验室成员（Lab member）

招生信息（admission information）

欢迎具有医学、农学、兽医学、生物学、病原生物学、结构生物学等学科背景的优秀学生加入本团队攻读硕士和博士研究生。

欢迎大学二年级（含）以上同学进入实验室参与有关科研学术工作，或联系毕业设计等。